In breast cancer, the expression levels of miR-30c-2-3p are characterized across patients with different molecular subtypes; lower expressions of miR-30c-2-3p are detected in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative groups compared to estrogen receptor (ER)-positive groups [37]. The gene discussed is ESR1; the disease is breast carcinoma.